Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity do not respond as strongly ...

Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies (colorized yellow) against the virus’ fusion protein — the target of RSV ...

Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity—primarily organ transplant ...

Zhu reengineered the RSV F protein by changing a pair of molecules ... Sarah Auclair, Robyn L. Stanfield, Linling He, and Ian A. Wilson of Scripps. This work was supported by funding from Uvax ...

Zhu reengineered the RSV F protein by changing a pair of molecules ... Sarah Auclair, Robyn L. Stanfield, Linling He, and Ian A. Wilson of Scripps. More information: Yi-Zong Lee et al, Rational ...

First, they must enter the host cells, which RSV does using its fusion (F) protein. Vaccines induce antibodies that bind to pathogens. Neutralizing antibodies bind to crucial sites, such as part ...

Today’s readout comes a couple of months after Enanta’s L-protein inhibitor, dubbed EDP-323, scored its own phase 2 win in RSV. That EDP-323 study raised “the high bar set by zelicapavir ...

The trimeric pre-fusion glycoprotein F is essential for accurately assessing the immunogenicity of RSV vaccines. We strictly adhere to regulations to provide high-quality, consistent, native ...

We report here CX3C chemokine mimicry for the G glycoprotein of respiratory syncytial virus (RSV) and show binding to CX3CR1—the specific receptor for the CX3C chemokine fractalkine—and ...

While RSV-attachment protein concentrations were statistically similar across vaccinated and unvaccinated cohorts, the former cohort expressed substantially higher overall anti-RSV antibody titers.